Biopharmaceuticals
News Release - January 9, 2012
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair(TM)* in COPD and Asthma
Source: Theravance
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.